Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. .National Taiwan University / 國立臺灣大學
  3. Project / 研究計畫
  4. Taiwan Clinical Trial Consortium for Renal Diseases (III) = 台灣急性腎損傷及腎病臨床試驗合作聯盟 (III)
 

Taiwan Clinical Trial Consortium for Renal Diseases (III) = 台灣急性腎損傷及腎病臨床試驗合作聯盟 (III)

  • Details
Project title
台灣急性腎損傷及腎病臨床試驗合作聯盟 (III)
Internal ID
MOST105-2325-B002-025
Principal Investigator
KWAN-DUN WU  
Start Date
May 1, 2016
End Date
April 30, 2017
Investigators
吳麥斯
吳哲熊
李進昌
陳靖博
盧國城
劉宏祥
VIN-CENT WU  
黃秋錦
吳志仁
楊雅斐
孫樵隱
郭美娟
唐德成
蕭志忠
TAO-MIN HUANG  
吳明儒
KUO-LIONG CHIEN  
YONG-CHANG CHEN  
Organizations
Internal Medicine  
Partner Organizations
National Science and Technology Council  
Keywords
Index words
Acute kidney injury
kidney disease
clinical study
multicenter randomized controlled trial
Description
The incidence rate of acute kidney injury (AKI) in hospitalized patients is increasing, and the number of deaths associated with dialysis-requiring AKI has more than doubled. Through strategies to lower the incidence of AKI and clarify the causal nature of the (acute kidney injury to chronic kidney disease) AKI-CKD relationship, further light will be shed on lowering the CKD burden by nipping it in the bud. CAKs will build a platform on which we share the clinical data and exchange state-of-the-art research information. Currently, the incidence rate of dialysis-requiring AKI is higher than that of end-stage renal disease (ESRD), and its annual growth rate is as high as 10% in the United States. To promote Taiwan Consortium of Acute Kidney Injury and Renal Diseases (CAKs) as the leading kidney diseases of the clinical trial group in Asia-Pacific by establishing a cohesive group of kidney clinical trial sites that conduct uniform standard-of-care and high quality clinical trial performance in renal diseases and provide credible and reliable data. The CAKs includes 30 hospitals which distribute widely through the four geographical regions (north, middle, south, and east) of Taiwan. The NEP-AKI-D study enrolls intensive care unit-based AKI patients who receive dialysis in the four seasonal sampled months (October 2014, along with January, April, and July 2015). The collected data include demographic information, pertaining laboratory results, dialysis settings, and patient outcomes. The outcomes of interest are in-hospital mortality, dialysis-dependency, and readmission rate within 90 days after discharge. The participating investigators of CAKs are specialists of kidney medicine who have experience in conducting bench and clinical studies of kidney diasese. The key missions of the CAKs will be to assist the design and conduct of multi-center investigator-initiated, industry or international research groups) clinical trials, as well as the establishment of biospecimen database of patients with kidney disease. The Central office will provide the window of communication, database auditing and the improving quality of specimens, and core study coordination. The core facility of CAKs will provide Standardized analysis for novel AKI biomarkers. Participating subjects need to sign the informed consent for clinical data, PBMC/plasma/serum/ specimens from kidney biopsy. In the initial first year, we have conducted 7 international clinical studies, applied and finished 4full ethical reviews by the institutional review board of NRPB in 2014. How about 2015? This year, we will work on 1. Improved AKI using “adsorbent” Clinical prospective multicenter randomized controlled trial (RCT) study.2. The Effect of Endotoxin Adsorbed Hemoperfusion on the Microcirculation in Patients with Severe Sepsis and Septic Shock. 3. Validation the device from Advanced Circuits Research Laboratory 4. The effects of medium-chain triglyceride on nutritional markers and quality of life in maintenance hemodialysis patients By estimation, the consortium has the ability to enroll patients with kidney disease and record the acute dialysis during intensive units. Core clinical information will be collected using a web based information system for future analysis. The ultimate goal for CAKs is to enable clinical trials of potential therapies for kidney diseases and speed the development of treatments that will improve the severity of end stage renal disease and mortality for patients with kidney diseases.

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science